Magdalena Kegel,  —

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

Articles by Magdalena Kegel

Pharma Giants Form UK-Based ‘Project Hercules’ to Generate Evidence for DMD Treatments

Seven pharmaceutical companies are banding together to sponsor Project Hercules — an initiative that addresses evidence generation for Duchenne muscular dystrophy (DMD) treatments. The project, led by the non-profit organization Duchenne UK, aims to simplify the way evidence is generated for health technology assessments by authorities such as Great Britain’s National…

Duchenne May Affect the Brain Too, Study Contends

Researchers have found that Duchenne muscular dystrophy patients usually have simultaneous neurological disorders or abnormalities, including epilepsy. Particularly, those who had epilepsy also had the neurodevelopmental condition attention deficit hyperactivity disorder (ADHD), or the neuropsychiatric conditions obsessive-compulsive disorder, anxiety or sleep disorders. Since the research, published in the European…

Capricor’s CAP-1002 Does More Than Repair DMD Hearts, Study Finds

A one-time infusion of Capricor Therapeutics’ heart progenitor cell therapy CAP-1002 improved heart muscle function and reduced tissue scarring in a small group of patients with Duchenne muscular dystrophy. The impact of the therapy, however, went beyond heart improvements, as the study demonstrated that CAP-1002 also improved hand and…

Forums CTA